louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT05688683: Brain Representation of Acquisition in Humans of Motor-Sensory Skills
Official title: Brain Representation of Acquisition in Humans of Motor-Sensory Skills
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Epilepsy
Cerebral Tumor
Lead sponsor: Fondation Ophtalmologique Adolphe de Rothschild
Sponsor class: NETWORK
First posted: 2023-01-18
Enrollment: 50
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: OTHER
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patient benefiting from an intracranial brain recording during a programmed surgery for epilepsy or cerebral tumor resection in awake condition.

Brief summary: Interactions between the perceptual and motor systems are fundamental to the performance of complex motor tasks and are at the heart of the fine motor control required for the production of complex sounds such as speech production or playing a musical instrument. In such situations, the brain must learn to generate relevant motor commands to a sound-producing system with fixed physical characteristics, such as the vocal tract or a musical instrument.

No study has yet been able to directly test the dynamic aspect of this sensorimotor learning in an acoustic production task with fine motor control.

The Adolphe de Rothschild Foundation Hospital takes care of patients requiring awake surgery. During these procedures, a direct cortical recording, called electro-corticography, is performed in order to better delineate the tumor or epileptogenic resection area. Reference recordings are made in healthy areas at a distance from the lesion site making it possible to record normal brain activity.

In this case, we would propose to the patient to use a tool similar to the theremin (a musical instrument the size of a golf ball whose displacement in space modulates the frequency and the harmonics of a sound). The patient should therefore learn in order to create relevant motor patterns.


Eligibility criteria: Inclusion Criteria:

* Benefiting from an intracranial brain recording during a programmed surgery in awake condition.

Exclusion Criteria:

* Patient with complete deafness
* Patient with a disorder or impairment that does not allow him/her to perform the experimental task according to the investigator's judgment

Primary outcomes:
measure: intracranial electroencephalography recording
timeFrame: Day 0
Secondary outcomes:
Other outcomes:
Locations:
city: Paris
country: France
facility: Fondation Adolphe de Rothschild
Study officials:
References:
Clinical trial NCT01051583: Avastin as an Adjunct to Diode Laser in the Treatment of Neovascular Glaucoma
Official title: Avastin as an Adjunct to Diode Laser Cyclophotoablation in the Treatment of Neovascular Glaucoma
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Neovascular Glaucoma
Keywords: Neovascular glaucoma
diode laser
cyclophotocoagulation
Avastin
Lead sponsor: Cairo University
Sponsor class: OTHER
Collaborators: name: AL-Nour Eye Hospital
name: Kasr El Aini Hospital
First posted: 2010-01-18
Enrollment: 16
Sex: ALL
Minimum age (years): 14
Maximum age (years): 72
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Assess the efficacy of Avastin as an adjunct to Diode Laser cyclophotocoagulation in the treatment of Neovascular Glaucoma.

Detailed description: Design: Prospective, comparative interventional case series. Method: Patients were randomly assigned into Group A which were treated with Diode laser cyclophotocoagulation alone, whereas group B received intravitreal Avastin (One milligram = 0.04mL of 25 mg/mL) in conjunction with the Diode Laser. The preoperative data included etiology, mean age; follow up period, and a full ophthalmological examination with emphasis on mean IOP, iris neovascularization, pain and corneal edema.

Eligibility criteria: Inclusion Criteria:

* Neovascular absolute glaucoma
* Painful blind eyes

Exclusion Criteria:

* Neovascular glaucoma with useful vision or potential for useful vision

Primary outcomes:
measure: Disappearance of iris neovessels
timeFrame: 2 weeks
Secondary outcomes:
measure: Intra ocular pressure
timeFrame: 4 weeks
Other outcomes:
Locations:
city: Cairo
country: Egypt
facility: Kasr El-Ainy hospital, Cairo university,ophthalmology departement
Study officials:
affiliation: Cairo University
name: Mostafa A EL-Helw, M.D.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00878683: Novel Device for Reducing Catheter-Related Infections
Official title: Exploring the Use of a Novel Device for Reducing Catheter-Related Bloodstream Infections
Study type: INTERVENTIONAL
Overall status: WITHDRAWN
Phase: NA
Conditions: Intensive Care
Lead sponsor: University of Kansas Medical Center
Sponsor class: OTHER
Collaborators: name: University of Missouri-Columbia
First posted: 2009-04-09
Enrollment: 0
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: SUPPORTIVE_CARE

Brief summary: This study is a pilot study of the safety, tolerability and efficacy of an investigational central venous catheter device used in conjunction with a standard central venous catheter. The hypothesis is that utilization of a catheter device incorporating cyanoacrylate will reduce catheter colonization by bacteria, and may decrease the rate of catheter-related bloodstream infections.


Eligibility criteria: Inclusion Criteria:

* Admission in the ICU at time of catheter insertion
* Indication for central venous catheter placement
* De novo catheter insertion in the subclavian or internal jugular veins

Exclusion Criteria:

* Anticipated catheter duration \< 72 hours
* Planned guidewire exchange
* Documented bacteremia within 48 hours prior to catheter placement
* Extensive skin breakdown near the site of potential catheter placement
* Emergent line placement
* Screening labs with ANC \< 500 or platelets \< 50K
* Hypersensitivity to cyanoacrylates or formaldehyde
* Prior enrollment in study

Primary outcomes:
measure: Catheter site inspection
timeFrame: Baseline, Daily
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
affiliation: University of Kansas Medical Center
name: Stephen Waller, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06624683: Exploring the Effect of Footbaths on Increasing the Success Rates in Vitro Fertilization
Official title: Exploring the Effect of Footbaths on Increasing the Success Rates of in Vitro Fertilization and Its Associated Mechanism
Study type: INTERVENTIONAL
Overall status: NOT_YET_RECRUITING
Phase: NA
Conditions: Infertility
In Vitro Fertilization
Keywords: Infertility
In vitro fertilization
Stress
Sleep quality
Inflammation
Footbath
Lead sponsor: National Taipei University of Nursing and Health Sciences
Sponsor class: OTHER
First posted: 2024-10-03
Enrollment: 80
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 45
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: To evaluate the effectiveness of warm-water footbaths in enhancing pregnancy rates during IVF and to explore the underlying mechanisms involved.

Detailed description: Additionally, this research will assess whether a complementary and alternative medicine (CAM) approach utilizing warm-water footbaths is effective in improving pregnancy rates for women undergoing IVF. Furthermore, the potential mechanisms by which footbaths may enhance IVF success rates will be elucidated.

The specific aims of this research proposal are as follows:

1. To explore the correlation between health statuses, sleep quality, stress, and infertility incidence.
2. To investigate the association between health statuses, sleep quality, stress, and multiple inflammatory indexes in infertile women, including:

   2-1. Systemic immune inflammation index (SII) 2-2. Lymphocyte count (LC) 2-3. Platelet and neutrophil count product (PPN) 2-4. Platelet-lymphocyte ratio (PLR) 2-5. Neutrophil-lymphocyte ratio (NLR) 2-6. Lymphocyte-monocyte ratio (LMR)
3. The effects of Footbaths on Stress and Sleep:

   To examine the effects of footbaths on reducing stress and improving sleep quality, which may enhance pregnancy success rates during IVF treatment in infertile women.
4. The impact on Inflammatory Markers:

To investigate whether footbaths can reduce levels of inflammatory markers and inflammatory cytokines during IVF treatment, potentially enhancing pregnancy success rates in infertile women.

Eligibility criteria: Inclusion Criteria:

* women aged 18\~45 years
* diagnosed with male factor infertility
* tubal factor infertility, or unexplained infertility, and undergoing an IVF treatment.

Exclusion Criteria:

* participants having adenomyosis, severe endometriosis
* a history of more than two IVF treatments
* any comorbidity or uncontrolled systemic diseases such as hypertension, diabetes, chronic heart disease or chronic renal disease that can affect the treatment process.

Primary outcomes:
measure: pregnancy rate
timeFrame: 28 days
Secondary outcomes:
Other outcomes:
Locations:
city: Taipei
country: Taiwan
facility: National Taipei University of Nursing and Health Sciences
Study officials:
affiliation: Taipei Veterans General Hospital, Taiwan
name: Chi-Hong Ho, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06412783: Population-based Investigation of Aneurysm Incidence
Official title: Population-based Investigation of Aneurysm Incidence
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Intracranial Aneurysm
Keywords: Intracranial Aneurysms
Screening
Blood test
Lead sponsor: Beijing Tiantan Hospital
Sponsor class: OTHER
First posted: 2024-05-14
Enrollment: 4711
Sex: ALL
Minimum age (years): 35
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: DIAGNOSTIC

Brief summary: Most intracranial aneurysms are found accidentally in neurovascular imaging. And these inspection methods are limited by the problems of instrument fixation, radiation, time-consuming, contrast agent toxicity and so on. At present, blood test is an ideal alternative method for early diagnosis. Compared with imaging examination, it is economical, general screening and convenient. Blood test is simple to operate, easy to be accepted by patients, and less invasive. Early screening of aneurysms can be performed.


Eligibility criteria: Inclusion Criteria:

* Age 35-75
* Individuals with normal cognitive and communication abilities
* No serious complications, such as uncontrolled hypertension, diabetes or other chronic diseases that may affect the test results.
* Basic blood test is normal or close to normal range.

Exclusion Criteria:

* Pregnancy
* Severe heart disease, renal insufficiency, liver dysfunction and other major diseases.
* In the past 6 months, there were strokes, or other types of intracranial tumors, infections and other diseases that may affect the screening results.
* There are metal implants, including dentures, pacemakers, etc.
* Using or recently used drugs that may affect blood biomarkers ( such as anticoagulant drugs, immunosuppressive agents, etc. ).
* There are serious mental illness or cognitive dysfunction, such as claustrophobia, unable to cooperate with the completion of the test.
* It is currently participating in other clinical trials or has participated in other clinical trials in the past 3 months.

Primary outcomes:
measure: Specific markers are detected
timeFrame: 1hours after blood collection
Secondary outcomes:
Other outcomes:
Locations:
city: Beijing
country: China
facility: Capital Medical University Affiliated Beijing Tiantan Hospital
state: Beijing
Study officials:
References:
Clinical trial NCT04371861: Observational Study to Assess Transradial Access for Treatment in the Lower Extremities.
Official title: Prospective, Multi-center, Observational, Post-market Study to Assess the Safety and Procedural Success of Performing Transradial Access for Treatment of Atherosclerotic Lesions in the Lower Extremities.
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Peripheral Arterial Disease
Lead sponsor: Terumo Medical Corporation
Sponsor class: INDUSTRY
First posted: 2020-05-01
Enrollment: 120
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Subjects planned to undergo treatment of a lower extremity lesion via transradial artery access.

Brief summary: This study is designed to collect data on the complication rates and procedural success of using a transradial access approach to treat peripheral lesions in the lower extremities of a real world population.


Eligibility criteria: Inclusion Criteria:

* Rutherford Category 2-5
* Subject scheduled for a transradial intervention to treat a lesion in the lower extremities.
* Willing to sign consent and agree to follow-up requirements.

Exclusion Criteria:

* Previous failed transradial access attempt
* Presence of or planned dialysis fistula.
* Planned amputation
* Previous or planned transradial access intervention +/- 30 days
* Radial artery diameter \<2.5mm
* No palpable radial artery
* Established vasospastic disease
* Known allergy to contrast that cannot be managed
* Pregnant or lactating
* Mentally incompetent or a prisoner
* Currently participating in a clinical study that has not completed it's primary endpoint

Primary outcomes:
measure: Radial access site complications
timeFrame: Procedure
measure: Procedural Success
timeFrame: Procedure
Secondary outcomes:
Other outcomes:
Locations:
city: La Jolla
country: United States
facility: UCSD
state: California
city: Saint Petersburg
country: United States
facility: Northside Hospital
state: Florida
city: Lafayette
country: United States
facility: Cardiovascular Institute of the South
state: Louisiana
city: Springfield
country: United States
facility: Mercy Hospital
state: Missouri
city: New York
country: United States
facility: Columbia University Medical Center
state: New York
city: New York
country: United States
facility: Sorin Medical, Inc.
state: New York
city: Cleveland
country: United States
facility: University Hospitals
state: Ohio
city: Kyle
country: United States
facility: Ascension Seton Hays Hospital
state: Texas
Study officials:
affiliation: University Hospitals, Cleveland, OH
name: Mehdi Shishehbor, DO
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02219061: Early Waning of Maternal Measles and Meningitis C Antibodies
Official title: Observation Study on Early Waning of Maternal Measles and Meningitis C Antibodies
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Measles
Keywords: Measles
Meningitis C
waning
Geometric Mean Titer
China
Lead sponsor: Guangzhou Center for Disease Control and Prevention
Sponsor class: OTHER_GOV
First posted: 2014-08-18
Enrollment: 100
Sex: ALL
Maximum age (years): 7
Standard ages: CHILD
Accepts healthy volunteers: yes
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Infants.

Brief summary: Maternal antibodies (measles and meningitis C) may wane in the first six months after birth.

* Geometric mean titers(GMTs) of measles and meningitis C.
* Follow-up on 0 month, 3rd month,5th month and 7th month after birth.

Detailed description: Measles and meningitis C are hot topics in China in recent years. Although China had set the goal of measles elimination, many measles cases were found to be those aged \< 8 months and meningitis C is becoming public health issue since meningitis group A has been controlled at a very low level and little is known on C group. So the investigators designed the observation study on the two antibodies.

Maternal antibodies are supposed to wane after birth. Serums of the placenta(0 month), children of 3 months, 5 months and 7 months old will be collected and the geometric mean titers (GMTs) of measles and meningitis C will be confirmed by using the ELISA test.

Eligibility criteria: Inclusion Criteria:

* Healthy infants.

Exclusion Criteria:

* Infants with poor score.

Primary outcomes:
measure: Geometric Mean Titer
timeFrame: Up to six months
Secondary outcomes:
Other outcomes:
Locations:
city: Guangzhou
country: China
facility: Guangzhou Center for Disease Control and Prevention
state: Guangdong
Study officials:
affiliation: Guangzhou CDC
name: Ming Wang
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05427461: Circulating " Cancer Cells / Macrophage " HYbrid Cells in Patients With Sarcoma, Part 2
Official title: Circulating " Cancer Cells / Macrophage " HYbrid Cells in Patients With Sarcoma, Part 2
Study type: INTERVENTIONAL
Overall status: ACTIVE_NOT_RECRUITING
Phase: NA
Conditions: Leiomyosarcoma
Keywords: Leiomyosarcoma
Cancer cell/macrophage hybrid cells
Hybrid cells
Lead sponsor: Institut Claudius Regaud
Sponsor class: OTHER
Collaborators: name: Fondation ARC
First posted: 2022-06-22
Enrollment: 20
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: OTHER

Brief summary: Pilot, prospective, monocentric study aimed at evaluating the rate of patients with circulating "cancer cell/macrophage" hybrid cells in the peripheral blood and the evolution of this rate over time.

The study will be conducted on a population of patients with leiomyosarcoma and treated in the context of routine care. 20 patients will be included:

* 10 patients with localized disease.
* 10 patients with metastatic disease.

For each included patient, blood samples will be collected during baseline visit and up to 24 months after inclusion.


Eligibility criteria: Inclusion Criteria:

1. Patient with leiomyosarcoma.
2. Diagnosis of sarcoma histologically confirmed by the RRePS network (Réseau de Référence en Pathologie des Sarcomes et des Viscères)
3. Localized or metastatic disease
4. Newly diagnosed patient who has not yet initiated specific treatment for sarcoma
5. Age ≥ 18 years
6. Patient affiliated to a Social Security system in France.
7. Patient having signed informed consent prior to inclusion in the study and prior to any specific study procedures

Exclusion Criteria:

1. Diagnosis of any other histological subtype of soft tissue sarcoma
2. Associated pathology(ies) that may interfere with the study procedure
3. Pregnant or breastfeeding woman
4. Any psychological, family, geographical or sociological condition that does not allow for compliance with the medical follow-up and/or procedures provided for in the study protocol.
5. Patient who has forfeited his/her freedom by administrative or legal award or who is under legal protection (curatorship and guardianship, protection of justice).

Primary outcomes:
measure: The longitudinal evolution of rate of patients with "cancer cell / macrophage" hybrid cells in peripheral blood.
timeFrame: 24 months after the end of inclusions.
Secondary outcomes:
measure: Quantification of circulating hybrid cells in peripheral blood by automatic measurement (Cell Counter Corning) and expressed in number of cells / millilitre of blood.
timeFrame: 24 months after the end of inclusions.
Other outcomes:
Locations:
city: Toulouse
country: France
facility: Institut Universitaire du Cancer Toulouse - Oncopole
Study officials:
References:
Clinical trial NCT03409861: 'Wristband Device for the Measurement of Intermittent Blood Pressure and Other Physiological Signals
Official title: Non-invasive, Non-Oscillometric Blood Pressure Band
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Blood Pressure
Lead sponsor: Hillel Yaffe Medical Center
Sponsor class: OTHER_GOV
First posted: 2018-01-24
Enrollment: 30
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Observational model: OTHER
Time perspective: OTHER
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Male and females over the age of 18 years Patients who are already fitted with and invasive Arterial Line (A-Line)

Brief summary: A wristband device intended for use as a standalone device, designed for the measurement of intermittent blood pressure, as well as other physiological signals. The device is intended to be worn in day to day life by individuals suffering from hypertension or other conditions where monitoring of blood pressure is of importance.

Detailed description: The device is intended to be worn on the wrist for intermittent measurements of vital signs such as HR, blood pressure, Skin temperature and activity.

The use does not require any special action from the user apart form wearing the band on either their left or right wrist. The device applies no inflatable mechanics or moving parts. The waistband is watertight and can be worn as any type of bracelet all the time of most of the time.

The study will focus on patients in intensive care or any other cardiology unit who are under continuous oversight of existing Invasive (A-line Gold Standard monitors

Eligibility criteria: Inclusion Criteria:

1. Signed written Institution approved Informed Consent Form (ICF)
2. Male and Females over the age of 18 years
3. Patients in intensive care or cardiology units who are under continuous oversight of existing Invasive (A-Line) Gold Standard monitors.
4. Only subjects who are fitted with an invasive Arterial Line (A LINE)
5. To the extent possible, individuals who have not been using medication 5 (five) hours prior to the test shall be classified as non-medicated subjects.

Exclusion Criteria:

1. Subject who are unable to provide consent
2. Where it would be impractical or inconvenient or otherwise unfeasible to place to place a wristband and generate a signal.
3. Subjects who are not fitted with, or not planned to be fitted with an A-Line during their stay in the hospital.

Primary outcomes:
measure: Blood Pressure Monitoring
timeFrame: 30-60 seconds of a clean signal from the A-line monitor
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
affiliation: Principal Investigator
name: Avraham Shotan, Prof
role: PRINCIPAL_INVESTIGATOR
References: